Gilead Sciences (NASDAQ:GILD) says the FDA has approved StribildT, a complete once-daily single tablet regimen for HIV-1 infection for treatment-naive adults. The drug - once referred to as the "Quad" prior to FDA approval - is a co-formulated HIV medicine that simplifies therapy by combining four compounds into one daily tablet. Shares +0.7% AH.
Gilead Sciences (NASDAQ:GILD) says the FDA has approved StribildT, a complete once-daily single...
Recommended For You
More Trending News
About GILD Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GILD | - | - |
Gilead Sciences, Inc. |